GemPharmatech Co

GemPharmatech Co Working Capital

The Working Capital of GemPharmatech Co (688046.SS) as of Oct 21, 2026 is 42.62 M CNY. In the previous year, Working Capital was 417.90 M CNY — a change of -89.80% (lower).

Working Capital

42.62 MCNY

YoY

-89.80%

Last updated:

Working Capital of GemPharmatech Co is 2025 42.62 M CNY. Working Capital of GemPharmatech Co was 2024 417.90 M CNY. It decreases by -89.80% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Working Capital of GemPharmatech Co is 42.62 M CNY in 2025.

Working Capital of GemPharmatech Co changed from 417.90 M CNY to 42.62 M CNY, representing a -89.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's GemPharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GemPharmatech Co

All Key Metrics — GemPharmatech Co